What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 481-485

  Huh, Warner ^a   Einstein, Mark H ^b   Herzog, Thomas J ^c   Franco, Eduardo L ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; HPV; Screening; Vaccination

Indexed keywords

VIRUS DNA;

CANCER IMMUNIZATION; CANCER PREVENTION; COLPOSCOPY; GENOTYPE; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; PAPANICOLAOU TEST; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; UTERINE CERVIX CANCER; VIRUS TYPING; WART VIRUS;

FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES;

EID: 77951939583     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.037     Document Type: Review

References (25)

1. Bosch F.X., and de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
2. Kjaer S., Hogdall E., Frederiksen K., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66 21 (Nov 1 2006) 10630-10636
3. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., and Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 168 2 (Jul 15 2008) 123-137
4. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 4 (Oct 2007) 346-355
5. Kulasingam S.L., Kim J.J., Lawrence W.F., et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 98 2 (Jan 18 2006) 92-100
6. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. Jama 287 18 (May 8 2002) 2382-2390
7. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 97 12 (Jun 15 2005) 888-895
8. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 3 (Aug 1 2007) 621-632
9. Herzog T.J., and Monk B.J. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol 197 6 (Dec 2007) 566-571
10. Huh W.K., and The Quadrivalent HPV Vaccine Phase IIb/III Investigators. Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18 virus-like particle vaccine on the incidence of abnormal Pap test and cervical procedures. Gynecol Oncol 108 (March 2008) S10 (Abstract #20)
11. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 5 (May 2005) 1157-1164
12. Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337 (Oct 13 2008) a1754
13. Franco E.L., Bosch F.X., Cuzick J., Schiller J.T., Garnett G.P., Meheus A., et al. Chapter 29: knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 24 Suppl 3 (Aug 31 2006) S3/242-9
14. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 Suppl 3 (Aug 31 2006) S3/171-S3/177
15. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
16. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132 10 (2000 May 16) 810-819
17. Cervical Cancer Screening. ACOG Practice Bulletin. Number 109, December 2009.
18. Kiviat N.B., Hawes S.E., and Feng Q. Screening for cervical cancer in the era of the HPV vaccine-the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 100 5 (2008 Mar 5) 290-291
19. Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., et al. Age-specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomized setting. J Natl Cancer Inst 101 23 (Dec 2 2009) 1612-1623
20. Guo M., Lin C.Y., Gong Y., et al. Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results. Mod Pathol 21 8 (Aug 2008) 1037-1043
21. Thrall M.J., Smith D.A., and Mody D.R. Women >/=30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women?. Diagn Cytopathol (2009 Nov 5) [Electronic publication ahead of print]
22. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 14 (2005 Jul 20) 1072-1079
23. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 14 (2005 Jul 20) 1066-1071
24. ASCCP 2009 Algorithm: Use of HPV Genotyping to Manage HPV HR * Positive/Cytology Negative Women 30 Years and Older (http://www.asccp.org/pdfs/consensus/hpv_genotyping_20090320.pdf).
25. Cervista Package Insert. http://www.cervista.com